A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

This Phase 1 study tests a new drug called ERX-315 in adults with advanced solid tumors — cancers that have spread or cannot be removed by surgery and have not responded to other treatments. ERX-315 is a first-in-class drug that works by targeting a specific pathway in cancer cells related to cholesterol processing inside the cell (a lysosomal cholesterol transport process). This early-phase study is focused on finding a safe dose and understanding how the drug behaves in the body. **You may be eligible if...** - You are 18 or older with a confirmed advanced or metastatic solid tumor — including but not limited to breast, ovarian, pancreatic, endometrial, or liver cancer - Standard treatments are no longer available or working for your cancer - You have measurable disease on a scan - You have adequate organ function and are in reasonably good health (ECOG 0 or 1) - Your expected survival is more than 3 months **You may NOT be eligible if...** - You received systemic cancer treatment within 4 weeks before starting - You had major surgery within 4 weeks before starting - You have a known enzyme deficiency affecting cholesterol storage (Wolman disease or CESD) - You have uncontrolled other serious illnesses Talk to your doctor to see if this trial is right for you.